Alkermes licenses Medifusion technology to build up TNF receptor-Fc fusion protein Alkermes.

Alkermes licenses Medifusion technology to build up TNF receptor-Fc fusion protein Alkermes, Inc. and Acceleron Pharma, Inc. The first drug candidate being created with this technology is a long-acting type of a TNF receptor-Fc fusion protein for the treating rheumatoid arthritis and related autoimmune diseases. Beneath the conditions of the agreement, Alkermes could have worldwide rights to the Medifusion technology in substitution for an upfront payment and equity investment in Acceleron as well as future advancement, regulatory and sales milestones and royalties on product sales. Acceleron shall retain all rights to the technology for items derived from the TGF-beta superfamily. Within the agreement, Acceleron will establish up to two chosen drug substances using the Medifusion technology through preclinical studies, at which point Alkermes will assume responsibility for all medical advancement and commercialization of the two compounds and any other substances Alkermes elects to develop resulting from the platform.Next, we’ll be hearing about young boys providing themselves HPV through masturbation! And the cries for vaccinating all young boys will end up being something along the relative lines of, If you masturbate, VACCINATE! Sadly, most individuals are therefore ignorant about reproductive health and germs in general that they’d probably buy into it. And if that advertising campaign is successful, they’ll move for the best stupid scare tactic: The Doorknob Marketing campaign . Warning: Doorknobs can provide you cancerHere’s how this advertising campaign works. To pull this off, the drug companies start floating scare tales about how anyone will get tumor by touching doorknobs.